ATE511348T1 - Transgenes modell für morbus alzheimer - Google Patents

Transgenes modell für morbus alzheimer

Info

Publication number: ATE511348T1
Authority: AT; Austria
Prior art keywords: alzheimer; disease; transgene; transgenic; transgenic model
Prior art date: 2004-03-22

Application number

AT05722229T

Other languages

English (en)

Inventor

Lars Nilsson

Lars Lannfelt

Paer Gellerfors

Original Assignee

Bioarctic Neuroscience Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-22

Filing date

2005-03-17

Publication date

2011-06-15

2005-03-17 Application filed by Bioarctic Neuroscience Ab filed Critical Bioarctic Neuroscience Ab

2011-06-15 Application granted granted Critical

2011-06-15 Publication of ATE511348T1 publication Critical patent/ATE511348T1/de

Links

208000024827 Alzheimer disease Diseases 0.000 title abstract 5
238000012301 transgenic model Methods 0.000 title 1
101710137189 Amyloid-beta A4 protein Proteins 0.000 abstract 2
102100022704 Amyloid-beta precursor protein Human genes 0.000 abstract 2
101710151993 Amyloid-beta precursor protein Proteins 0.000 abstract 2
108700019146 Transgenes Proteins 0.000 abstract 2
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
230000035772 mutation Effects 0.000 abstract 2
230000009261 transgenic effect Effects 0.000 abstract 2
108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
238000003745 diagnosis Methods 0.000 abstract 1
239000000032 diagnostic agent Substances 0.000 abstract 1
229940039227 diagnostic agent Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000003834 intracellular effect Effects 0.000 abstract 1
230000008506 pathogenesis Effects 0.000 abstract 1
230000001717 pathogenic effect Effects 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
238000012216 screening Methods 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Environmental Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Wood Science & Technology (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
Toxicology (AREA)
Microbiology (AREA)
Animal Husbandry (AREA)
Biodiversity & Conservation Biology (AREA)
Plant Pathology (AREA)
Neurology (AREA)
Physics & Mathematics (AREA)
Gastroenterology & Hepatology (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Investigating Or Analysing Biological Materials (AREA)
Eye Examination Apparatus (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT05722229T 2004-03-22 2005-03-17 Transgenes modell für morbus alzheimer ATE511348T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE0400707A SE0400707D0 (sv)	2004-03-22	2004-03-22	Transgenic animal model
PCT/SE2005/000383 WO2005089539A1 (en)	2004-03-22	2005-03-17	Transgenic model for alzheimer’s disease

Publications (1)

Publication Number	Publication Date
ATE511348T1 true ATE511348T1 (de)	2011-06-15

Family

ID=32067463

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05722229T ATE511348T1 (de)	2004-03-22	2005-03-17	Transgenes modell für morbus alzheimer

Country Status (10)

Country	Link
US (1)	US7709695B1 (de)
EP (1)	EP1729569B1 (de)
JP (1)	JP4914343B2 (de)
AT (1)	ATE511348T1 (de)
AU (1)	AU2005224992B2 (de)
CA (1)	CA2560551A1 (de)
DK (1)	DK1729569T3 (de)
ES (1)	ES2367310T3 (de)
SE (1)	SE0400707D0 (de)
WO (1)	WO2005089539A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002003911A2 (en)	2000-07-07	2002-01-17	Lars Lannfelt	Prevention and treatment of alzheimer's disease
SE0401601D0 (sv)	2004-06-21	2004-06-21	Bioarctic Neuroscience Ab	Protofibril specific antibodies and uses thereof
ATE492561T1 (de)	2006-03-23	2011-01-15	Bioartic Neuroscience Ab	Verbesserte protofibrilselektive antikörper und deren verwendung
US9688734B2 (en)	2008-04-14	2017-06-27	Alzinova Ab	Stable amyloid beta monomers and oligomers
KR101634244B1 (ko) *	2014-06-19	2016-06-29	한경대학교 산학협력단	Talen을 이용하여 grk5 넉아웃 마우스를 제조하는 방법
PL3166970T3 (pl)	2014-07-10	2021-09-13	Bioarctic Ab	Ulepszone przeciwciała wiążące protofibryle a-beta
EP3224380A1 (de)	2014-11-25	2017-10-04	The Broad Institute Inc.	Klonale hämatopoese
EP3626832B1 (de)	2014-11-25	2024-06-12	The Brigham and Women's Hospital, Inc.	Verfahren zur identifizierung einer person mit einer prädisposition für eine kardiometabolische krankheit oder eine davon betroffene person
JP2022543446A (ja) *	2020-02-28	2022-10-12	アールズィーノミクス・インコーポレイテッド	Ａｐｏｅ４ｒｎａ特異的トランススプライシングリボザイム及びその用途
CN113957095A (zh) *	2021-10-22	2022-01-21	江苏集萃药康生物科技股份有限公司	一种用于构建阿尔兹海默症动物模型的构建方法及其核酸组合物和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2204899T3 (es)	1992-01-07	2004-05-01	Elan Pharmaceuticals, Inc.	Modelos de animales transgenicos para la enfermedad de alzheimer.
US5604102A (en)	1992-04-15	1997-02-18	Athena Neurosciences, Inc.	Methods of screening for β-amyloid peptide production inhibitors
US5455169A (en)	1992-06-04	1995-10-03	Alzheimer's Institute Of America, Inc.	Nucleic acids for diagnosing and modeling Alzheimer's disease
US5449604A (en)	1992-10-21	1995-09-12	University Of Washington	Chromosome 14 and familial Alzheimers disease genetic markers and assays
JPH09507746A (ja)	1993-10-27	1997-08-12	アテナニューロサイエンシズ，インコーポレイティド	Ｓｗｅｄｉｓｈ変異を有するＡＰＰ対立遺伝子を含有するトランスジェニック動物
US5877399A (en)	1994-01-27	1999-03-02	Johns Hopkins University	Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
JPH07238035A (ja) *	1994-02-28	1995-09-12	Kyowa Hakko Kogyo Co Ltd	βアミロイド蛋白質分解剤
US5777194A (en)	1995-04-26	1998-07-07	Cephalon, Inc.	Gene-targeted mice with humanized Aβ sequence and Swedish FAD mutation
US5986054A (en)	1995-04-28	1999-11-16	The Hospital For Sick Children, Hsc Research And Development Limited Partnership	Genetic sequences and proteins related to alzheimer's disease
US6717031B2 (en)	1995-06-07	2004-04-06	Kate Dora Games	Method for selecting a transgenic mouse model of alzheimer's disease
ATE394481T1 (de)	1996-07-24	2008-05-15	Novartis Pharma Gmbh	Transgentier-modell für die krankheit von alzheimer
US5898094A (en)	1996-10-21	1999-04-27	University Of South Florida	Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
US20030131364A1 (en)	1999-04-27	2003-07-10	Karen Duff	Method for producing transgenic animal models with modulated phenotype and animals produced therefrom
WO2002003911A2 (en)	2000-07-07	2002-01-17	Lars Lannfelt	Prevention and treatment of alzheimer's disease
US7196163B2 (en) *	2001-05-22	2007-03-27	Merk & Co., Inc.	Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity
US20040248766A1 (en) *	2001-06-18	2004-12-09	Andrea Leblanc	Selective inhibition of intracellular amyloid-beta neurotoxicity in human neurons
JP2006505272A (ja) *	2002-11-04	2006-02-16	バイオアークティックニューロサイエンスアーベー	βアミロイド前駆体タンパク質の構造およびプロセシングを調節する薬剤の同定のための方法
US20040255341A1 (en) *	2003-10-21	2004-12-16	Envivo Pharmaceuticals, Inc.	Transgenic flies expressing Abeta42-Arctic

2004
- 2004-03-22 SE SE0400707A patent/SE0400707D0/xx unknown
2005
- 2005-03-17 JP JP2007504909A patent/JP4914343B2/ja not_active Expired - Fee Related
- 2005-03-17 EP EP05722229A patent/EP1729569B1/de not_active Not-in-force
- 2005-03-17 ES ES05722229T patent/ES2367310T3/es active Active
- 2005-03-17 US US10/593,639 patent/US7709695B1/en not_active Expired - Fee Related
- 2005-03-17 DK DK05722229.1T patent/DK1729569T3/da active
- 2005-03-17 AT AT05722229T patent/ATE511348T1/de active
- 2005-03-17 WO PCT/SE2005/000383 patent/WO2005089539A1/en active Application Filing
- 2005-03-17 AU AU2005224992A patent/AU2005224992B2/en not_active Ceased
- 2005-03-17 CA CA002560551A patent/CA2560551A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP4914343B2 (ja)	2012-04-11
EP1729569B1 (de)	2011-06-01
ES2367310T3 (es)	2011-11-02
SE0400707D0 (sv)	2004-03-22
JP2007530035A (ja)	2007-11-01
AU2005224992A1 (en)	2005-09-29
CA2560551A1 (en)	2005-09-29
US7709695B1 (en)	2010-05-04
AU2005224992B2 (en)	2010-05-06
DK1729569T3 (da)	2011-09-19
EP1729569A1 (de)	2006-12-13
WO2005089539A1 (en)	2005-09-29

Legal Events

Date

Code

Title

Description

2012-01-15

UEP

Publication of translation of european patent specification

Ref document number: 1729569

Country of ref document: EP

Publication	Publication Date	Title
ATE511348T1 (de)	2011-06-15	Transgenes modell für morbus alzheimer
Casas et al.	2004	Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Aβ42 accumulation in a novel Alzheimer transgenic model
Radde et al.	2008	The value of incomplete mouse models of Alzheimer’s disease
Saraceno et al.	2013	Modeling Alzheimer’s disease: from past to future
AU8448301A (en)	2002-03-22	Remedies for heart failure
WO2006052691A3 (en)	2007-05-10	Pet and magnetic resonance for screening alzheimer's disease therapeutics
BRPI0510123A (pt)	2007-09-25	modelos transgênicos de doença de alzheimer e seu uso no tratamento de uma variedade de doenças neurodegenerativas
WO2004007722A3 (en)	2004-03-25	Transgenic animal expressing alzheimer’s tau protein
Tanaka et al.	2006	Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin
EA200702095A1 (ru)	2008-04-28	Антитела, направленные против бета-амилоидного пептида, и способы их использования
WO2007149293A3 (en)	2008-12-04	Transgenic flies expressing tau and amyloid precursor fragment
Hundelt et al.	2011	Altered phosphorylation but no neurodegeneration in a mouse model of tau hyperphosphorylation
Willuweit et al.	2009	Early-onset and robust amyloid pathology in a new homozygous mouse model of Alzheimer's disease
Garringer et al.	2013	Increased tau phosphorylation and tau truncation, and decreased synaptophysin levels in mutant BRI2/tau transgenic mice
ATE548453T1 (de)	2012-03-15	Material und methoden, involviert in die protein- aggregation neurodegenerativer krankheiten
Lee et al.	2006	Progressive neuronal loss and behavioral impairments of transgenic C57BL/6 inbred mice expressing the carboxy terminus of amyloid precursor protein
ATE541923T1 (de)	2012-02-15	Transgener c. elegans als modellorganismus für untersuchungen zur alzheimer'schen krankheit
ATE323408T1 (de)	2006-05-15	Transgenes tiermodell für neurodegenerative erkrankungen
IL174726A (en)	2013-05-30	Non-human animals with transgenic nucleic acid encoded by a mutant perinylin 1 protein
WO2003093442A3 (en)	2004-04-01	Cell cultures from animal models of alzheimer's disease for screening and testing drug efficacy
DE60121324D1 (de)	2006-08-17	Tiermodel für neurodegenerative erkrankungen
Wittnam	2012	The contribution of N-terminally modified amyloid beta to the etiology of Alzheimer's disease
WO2004062627A3 (en)	2005-03-03	In vivo screening models for treatment of alzheimer's disease and other neurodegenerative disorders
ATE396263T1 (de)	2008-06-15	Transgenes tiermodel für neurodegenerative erkrankungen
ATE460673T1 (de)	2010-03-15	Screeningverfahren zum identifizieren protektiver substanzen für die behandlung neurodegenerativer und/oder ischämischer erkrankungen